← 返回前沿论文

双 CD19 和 CD22 靶向 CAR-T 细胞疗法在 TCF3-HLF 阳性复发/难治性 B 细胞急性淋巴细胞白血病儿科患者中实现持久缓解

英文原题:Durable remission achieved in pediatric patients with TCF3-HLF-positive relapsed/refractory B-cell acute lymphoblastic leukemia by dual CD19- and CD22-targeted chimeric antigen receptor T-cell therapy.

PubMed 2025/05/22(内容时间) Haematologica Q1 · IF 8.2(JCR 2025)

摘要

这条还没有中文摘要(正在补翻译)。 可以先展开下面的英文原文,或点最下面的「在 PubMed 查看」读原文献。

论文信息

作者
Wan X、Wang T、Yang J、Yang X、Li W、Ding L、Yang L、Zhang J
第一作者单位
Department of Hematology and Oncology, Key laboratory of Pediatric Hematology and Oncology Ministry of Health, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine, Shanghai.China
通讯作者单位
Department of Hematology and Oncology, Key laboratory of Pediatric Hematology and Oncology Ministry of Health, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine, Shanghai. libenshang@scmc.com.cn.China
期刊
Haematologica2026 Jan 1
原文标识
PubMed 40400462 · DOI 10.3324/haematol.2024.287023